Ro 64-5229Selective, non-competitive mGlu2 antagonist CAS# 246852-46-0 |
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- WHI-P180 hydrochloride
Catalog No.:BCC4243
CAS No.:153437-55-9
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- RGB-286638
Catalog No.:BCC5519
CAS No.:784210-87-3
- AT7519 Hydrochloride
Catalog No.:BCC1376
CAS No.:902135-91-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 246852-46-0 | SDF | Download SDF |
PubChem ID | 10428048 | Appearance | Powder |
Formula | C17H19Cl2N3O | M.Wt | 352.26 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | 1-[(Z)-2-cycloheptyloxy-2-(2,6-dichlorophenyl)ethenyl]-1,2,4-triazole | ||
SMILES | C1CCCC(CC1)OC(=CN2C=NC=N2)C3=C(C=CC=C3Cl)Cl | ||
Standard InChIKey | STCVFKBRXOEQRF-YBEGLDIGSA-N | ||
Standard InChI | InChI=1S/C17H19Cl2N3O/c18-14-8-5-9-15(19)17(14)16(10-22-12-20-11-21-22)23-13-6-3-1-2-4-7-13/h5,8-13H,1-4,6-7H2/b16-10- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective, non-competitive mGlu2 antagonist. Inhibits GTPγ35S binding to mGlu2-containing membranes (IC50 = 0.11 μM). |
Ro 64-5229 Dilution Calculator
Ro 64-5229 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8388 mL | 14.1941 mL | 28.3881 mL | 56.7762 mL | 70.9703 mL |
5 mM | 0.5678 mL | 2.8388 mL | 5.6776 mL | 11.3552 mL | 14.1941 mL |
10 mM | 0.2839 mL | 1.4194 mL | 2.8388 mL | 5.6776 mL | 7.097 mL |
50 mM | 0.0568 mL | 0.2839 mL | 0.5678 mL | 1.1355 mL | 1.4194 mL |
100 mM | 0.0284 mL | 0.1419 mL | 0.2839 mL | 0.5678 mL | 0.7097 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Catharanthine
Catalog No.:BCN1255
CAS No.:2468-21-5
- 3-Amino-2,6-piperidinedione hydrochloride
Catalog No.:BCC8606
CAS No.:24666-56-6
- Neolitsine
Catalog No.:BCN4817
CAS No.:2466-42-4
- Stellasterol
Catalog No.:BCN5110
CAS No.:2465-11-4
- H-Isoleucinol
Catalog No.:BCC2726
CAS No.:24629-25-2
- 3-Geranyl-4-methoxybenzoic acid
Catalog No.:BCN5109
CAS No.:246266-38-6
- AL 8810
Catalog No.:BCC5366
CAS No.:246246-19-5
- H-Phe-OBzl.HCl
Catalog No.:BCC3006
CAS No.:2462-32-0
- BIIE 0246
Catalog No.:BCC7158
CAS No.:246146-55-4
- trans-4-Hydroxycrotonic acid
Catalog No.:BCC6685
CAS No.:24587-49-3
- Rubrofusarin-6-O-beta-D-gentiobioside
Catalog No.:BCN1476
CAS No.:24577-90-0
- TC-G 1000
Catalog No.:BCC7991
CAS No.:245744-18-7
- 1-Benzoyl-4-oxopiperidine
Catalog No.:BCC8455
CAS No.:24686-78-0
- Aglinin A
Catalog No.:BCN5111
CAS No.:246868-97-3
- Derrisisoflavone B
Catalog No.:BCN3955
CAS No.:246870-75-7
- Senegenin
Catalog No.:BCN5899
CAS No.:2469-34-3
- Uvedalin
Catalog No.:BCN4665
CAS No.:24694-79-9
- Chlorouvedalin
Catalog No.:BCN4664
CAS No.:24694-80-2
- Leonurine hydrochloride
Catalog No.:BCN6286
CAS No.:24697-74-3
- Isomangiferin
Catalog No.:BCN2528
CAS No.:24699-16-9
- NVP DPP 728 dihydrochloride
Catalog No.:BCC2365
CAS No.:247016-69-9
- Weinreb Linker
Catalog No.:BCC2836
CAS No.:247021-90-5
- 7beta-Methoxyrosmanol
Catalog No.:BCN7965
CAS No.:24703-38-6
- 6-Deoxy-9alpha-hydroxycedrodorin
Catalog No.:BCN5112
CAS No.:247036-52-8
Anti-La positive, anti-Ro negative subset of primary Sjogren's syndrome: anti-La is a reality but is the disease?[Pubmed:28229827]
Clin Exp Rheumatol. 2017 May-Jun;35(3):438-444. Epub 2017 Feb 20.
OBJECTIVES: To characterise the serological and clinical findings in primary Sjogren's syndrome in which anti-La was found without anti-Ro. We hypothesised that a significant portion of these are falsely negative for anti-Ro60. METHODS: Twenty-nine sera from primary Sjogren's syndrome patients were tested for antibodies directed against La and Ro. Anti-La was detected using bovine La treated with or without DNAase and RNAase to identify potential false positivity. Anti-Ro60 antibodies were detected using HEp-2000 substrate (in which cells are transfected with human Ro60) and HEp-2 substrate. Anti-Ro60 and Ro-52 were also tested by in vitro transcription/translation followed by immunoprecipitation assay. RESULTS: All 29 sera bound La, even after treatment with DNAase and RNAase. Of the 29 sera, 25 were unequivocally negative on HEp-2000 (1:40 dilution). Four samples were anti-Ro60 positive with a speckled pattern, three of the four at 1:320 dilution. Thus, false negative anti-Ro60 exists in a small fraction (14%) of the Ro-negative/La-positive primary Sjogren's patients. However, all the samples were negative for Ro60 and Ro52 by in vitro immunoprecipitation assay. Clinically these patients tended not to have salivary gland pathology characteristic of Sjogren's syndrome. CONCLUSIONS: We found only a small fraction of Ro negative/La positive sera to show positive HEp-2000 pattern. These subjects did not have characteristic findings on pathological examination of minor salivary glands, suggesting these subjects have a process distinct from Sjogren's syndrome.
Spontaneous Remission of Congenital Complete Atrioventricular Block in Anti-Ro/La Antibody-Negative Monozygotic Twins: Case Report.[Pubmed:28251027]
Balkan Med J. 2017 Jan;34(1):71-73.
BACKGROUND: Congenital complete atrioventricular block without any structural heart disease and anti-Ro/La negativity is very rare. Discordant complete atrioventricular block, which is more frequently defined in the literature as an autoimmune mechanism, is much more rare in monozygotic twins. CASE REPORT: The 26-year-old healthy mother had given birth in her first spontaneous, uneventful pregnancy to monozygotic twins at week 35. While the first twin's physical examination proved her to be normal with a pulse rate consistent with her age, the second twin had a pulse rate of approximately 40 beats/minute.The patient was confirmed to have congenital complete atrioventricular block. CONCLUSION: Despite this case appears to be an isolated one, a discordant complete atrioventricular block regression without any autoimmune evidence should be included in the differential diagnosis of bradycardia in infants.
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block.[Pubmed:28204891]
Clin Rheumatol. 2017 May;36(5):1155-1160.
Congenital heart block (CHB) is an autoantibody mediated disorder presumably caused by placental transmission of maternal autoantibodies to Ro/SSA 52 kd, p200, Ro/SSA 60 kd, La/SSB ribonucleoproteins. This study investigated the clinical significance of isolated anti-Ro/SSA 52 kd, anti-p200, anti-Ro/SSA 60 kd, and anti-La/SSB antibodies in positive pregnant patients. One hundred sixty-three pregnant women positive to anti-Ro/SSA 52 kd and/or anti-Ro/SSA 60 kd and/or anti-La/SSB antibodies were prospectively enrolled in the study. Anti-Ro52, anti-Ro60, anti-p200, and anti-La antibodies were assayed using home-made ELISA assays. Isolated antibody positivity was found in 25 women (15.3%), while multiple antibody positivity in 138 (84.7%). Twenty-four developed CHB, and the 139 had a favorable pregnancy outcome. The prevalence of isolated anti-Ro/SSA 60 kd antibodies was significantly higher (p < 0.046) as the prevalence of lower mean antibody titers (p < 0.0001) in the later group. Confirmation of these results by large-scale studies could lead clinicians to recommend less stringent fetal echocardiography monitoring in women with isolated anti-Ro/SSA 60 kd antibodies.
Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature.[Pubmed:28212920]
Autoimmun Rev. 2017 Apr;16(4):427-432.
Neonatal Lupus Syndrome (NLS) is a distinct clinical entity caused by transplacental passage of maternal anti-SSA/Ro antibodies (Ab). Mothers may have systemic lupus erythematosus, Sjogren syndrome, or other connective tissue disease, or may be completely healthy at the time of giving birth. NLS includes several clinical manifestations: complete congenital heart block (CCHB) and cutaneous lupus are the most common, while hepatobiliary disease, hematological manifestations and central nervous system involvement may occur. Data from literature on the incidence of the different clinical manifestations of NLS are difficult to compare because they come mostly from retrospective studies or prospective studies, but up to date no systematic follow-up was carried out. We performed a large prospective single-center study with a systematic clinical and instrumental follow-up until 9months of life, in order to evaluate the incidence and the clinical impact of NLS features. From 2004 to 2014 all infants born in our center to mothers with anti-SSA/Ro Ab were enrolled in a specific diagnostic and follow-up (FU) program. At birth, 50 infants born to mothers with anti-SSA/Ro Ab were found positive for anti-SSA/Ro Ab. Infants were tested for anti SSA/Ro Ab at 3months of life, if positive they were re-tested at 6 and 9months. At 9months anti-SSA/Ro Ab were positive in 10% of children. In two cases (4%) a CCHB was identified during pregnancy and required pacemaker implantation at birth. In 10% of cases a transient ECG alterations was found during follow-up. Hematological NLS features (anemia, neutropenia, thrombocytopenia) were found at birth and during FU in several patients, in all cases without clinical manifestations and in most cases with complete normalization at 9months. Mild and transient elevation of aminotransferases between 3 and 6months of life were found in 56% and 40% of patient, respectively; non-specific ultrasound cerebral anomalies in absence of clinical neurological signs were found at birth in 9 patients (18%), subsequently normalized. Prenatal maternal screening is of primary importance in order to early detect CCHB, which requires maternal treatment and pacemaker implantation at birth. Infants born to mothers with anti-SSA/Ro Ab should be monitored for all NLS features at birth. However, during the first months of life, these infants seem to develop only mild, transient and self-limited clinical manifestations, which in most cases are completely solved at 9months of life. This consideration, together with the evidence that only 10% of infants had anti-SSA/Ro Ab persistent in blood at 9months, suggests that follow-up of these children can be performed until 6-9months of life with good clinical safety. Moreover, a clinical and laboratory monitoring at 3months of life, when the highest incidence of hematological features and liver tests alterations are observed, is strongly recommended. In the future, it would be clarified if a follow-up until adulthood would be indicated in cases with persistent anti SSA/Ro or in all infants born to mother with anti SSA/Ro.
Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors.[Pubmed:17266540]
Curr Drug Targets. 2007 Jan;8(1):169-84.
Family C of G-protein coupled receptors (GPCRs) from humans is constituted by eight metabotropic glutamate (mGlu(1-8)) receptors, two heterodimeric gamma-aminobutyric acid(B) (GABA(B)) receptors, a calcium-sensing receptor (CaR), three taste (T1R) receptors, a promiscuous L-alpha-amino acid receptor (GPRC6A), and five orphan receptors. Aside from the orphan receptors, the family C GPCRs are characterised by a large amino-terminal domain, which bind the endogenous orthosteric agonists. Recently, a number of allosteric modulators binding to the seven transmembrane domains of the receptors have also been reported. Family C GPCRs regulate a number of important physiological functions and are thus intensively pursued as drug targets. So far, two drugs acting at family C receptors (the GABA(B) agonist baclofen and the positive allosteric CaR modulator cinacalcet) have been marketed. Cinacalcet is the first allosteric GPCR modulator to enter the market, which demonstrates that the therapeutic principle of allosteric modulation can also be extended to this important drug target class. In this review we outline the structure and function of family C GPCRs with particular focus on the ligand binding sites, and we present the most important pharmacological agents and the therapeutic prospects of the receptors.
Synthesis of heterocyclic enol ethers and their use as group 2 metabotropic glutamate receptor antagonists.[Pubmed:10465539]
Bioorg Med Chem Lett. 1999 Aug 2;9(15):2173-6.
Heterocyclic enol ethers of type 1 were studied with respect to the inhibition of 1S,3R-ACPD (10 microM)-stimulated GTP gamma35S binding on rat mGluR2 transfected cell membranes. The structure activity relationship with regard to the substitution pattern of the phenyl ring, the oxygen substituent and the nature of the heterocycle is discussed.